Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which lung biopsy is safest and most accurate? new study has answers

NCT ID NCT07432503

Diagnosis Sponsor: Mansoura University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at three ways to take a small sample of lung tissue (biopsy) in 60 adults with interstitial lung diseases. The goal was to find which method gives the most accurate diagnosis and causes the fewest side effects. The methods tested were forceps biopsy, cryobiopsy (using extreme cold), and thoracoscopic biopsy (a minimally invasive surgery). Results help doctors choose the best technique for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

May 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age more than 18 years * patients with no absolute contraindications for procedure * cases who had clinical, laboratory and radiological criteria of ILD Exclusion Criteria: * patients with images typical of definite UIP and definite extrinsic allergic alveolitis * clinical and radiological evidence of occupational lung diseases * coagulation disorder, advanced uncompensated heart disease, uncompensated Type II Respiratory failure, severe grades of pulmonary hypertension * pulmonary metastasis or lymphangitis carcinomatosis * specific parenchymal pattern "honeycombing, probable UIP, diffuse end stage fibrosis, cystic lung diseases and advanced LAM and PLCH

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypersenstivity pneumonitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypersensitivity pneumonitis interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypersenstivity pneumonitis Interstitial lung diseases (ILD)

Contacts and locations

Locations

  • Mansoura University Hospitals ,Chest Medicine Department

    Al Mansurah, Dakahlia Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.